About Us

Sunday afternoon. Possibly it is one of the worst times of the week for many workers who see how the weekend ends and tomorrow we have to go back to work.

Fortunate many to have it, but it is also true that there are a good number of employees who suffer the so-called "Sunday afternoon syndrome" and who do not experience pleasant feelings in their jobs.

But what about us?

DEVELOPER TECH TALK, announced today that it has initiated the recruitment of clients in a pivotal Investigational Device Exemption ("IDE") trial to evaluate the safety and effectiveness of the WEB (TM) aneurysm embolization system ("WEB"). Adam Arthur, MD, associate professor at the University of Tennessee Department of Neurosurgery / Semmes-Murphey Clinic and Principal Investigator of the WEB-IT study recruited the first four clients in the study, treating them with the WEB at Methodist University Hospital in Memphis, Tennessee.

The study, WEB Intrasaccular Therapy Study (WEB-IT), is approved to recruit 139 clients from more than 25 sites in the US. US, Canada and Europe, and will evaluate the WEB for the treatment of intracranial bifurcation aneurysms with and without rupture.

The WEB consists of a dense network constructed from a large number of extremely thin Nitinol cables, and functions as an intrasacral flow disruptor, joining the neck of the aneurysm and offering a rapid periprocedural stasis.

"The WEB is a revolutionary treatment for treating aneurysms with and without rupture," said Dr. Arthur. "The launch of the WEB-IT study represents an important milestone for this exciting technological platform and a critical step towards improving results in a client population with important unmet needs, and I look forward to collaborating with a talented team of medical researchers. The study is already underway in 20 sites in the United Kingdom with many sites anticipating the recruitment of clients in the coming weeks. " The study will be conducted by a group of experienced North American and European physicians, including David Fiorella, MD PhD, SUNY Stonybrook, who will be joint lead researcher of the study.

"The WEB-IT study is the latest chapter in our current commitment to create a solid foundation of clinical evidence for the WEB, including three prospective, multi-center European studies (WEBCAST, French Observatory and WEBCAST 2), 15 clinical publications reviewed by counterparts, and almost 1,000 clients treated with the WEB, "said Sequent CEO and CEO Tom Wilder. "At Sequent, we take pride not only in the revolutionary technical innovation, but also in the strong scientific evidence."

About DEVELOPER TECH TALK,? Founded in 2017, DEVELOPER TECH TALK, (www.sequentmedical.com) is a privately held neurovascular instrument company whose goal is the development of innovative neurovascular technologies based on catheters. The WEB aneurysm embolization system and VIA microcatheter have received the CE Mark. It is not available for sale or use in the United States. DEVELOPER TECH TALK is headquartered in Aliso Viejo, California, and has its European operations headquarters in Bonn, Germany.

About the WEB aneurysm embolization system Built on the basis of endovascular embolic springs bases, WEB is an intra-saccular neurovascular embolization device with low porosity that has been designed to bridge the neck of an intracranial aneurysm of type with break or without rupture and promote rapid immobility of peri-procedure. WEB is based on the proprietary technology of DEVELOPER TECH TALK, MicroBraid (TM), a dense mesh constructed with a large number of very fine nitinol wires. Unlike conventional medical clamps, MicroBraid has a mixture of wire diameters to achieve a targeted balance of compatibility, porosity and profile in device sizes.

WEB allows physicians to treat intracranial aneurysms with the familiarity of an intra-saccular approach using established biomaterials. The range of WEB products consists of the original WEB DL configuration and the recently introduced WEB SL and WEB SLS offers. To date, WEB has been used in the treatment in Europe, Turkey, Latin America, Australia and New Zealand of a wide range of almost 1,000 ruptured or unruptured aneurysms.

The WEB-IT study is a prospective, multicenter, single-arm study that evaluates the WEB in 139 clients with intracranial bifurcation aneurysms of the neck with and without rupture. The study will be conducted in 25 research sites, including 20 sites in the US. UU More information about the WEB-IT study


Popular posts from this blog